Liposome battle for antifungal market shifts into high gear.

  title={Liposome battle for antifungal market shifts into high gear.},
  author={Stephen Marks},
  journal={Journal of the International Association of Physicians in AIDS Care},
  volume={2 4},
  • Stephen Marks
  • Published 1996 in
    Journal of the International Association of…
Three new and improved forms of amphotericin B (AmBisome, Amphocil, and Abelcet), all based on various lipid formulations, have become available for treatment against fungal infections in immunocompromised patients. Abelcet, the first of the three drugs, received FDA approval in November 1995 for treatment of aspergillosis. Favorable decisions by the FDA on the other two drugs are expected. Each drug transports higher doses of amphotericin B while minimizing exposure to sensitive organs. Choice… CONTINUE READING